Imazodan

CAS No. 84243-58-3

Imazodan( —— )

Catalog No. M36381 CAS No. 84243-58-3

Imazodan, a small molecule compound with positive inotropic activity, is a selective type III phosphodiesterase inhibitor and can be used to study heart failure.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 42 In Stock
10MG 50 In Stock
25MG 72 In Stock
50MG 104 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Imazodan
  • Note
    Research use only, not for human use.
  • Brief Description
    Imazodan, a small molecule compound with positive inotropic activity, is a selective type III phosphodiesterase inhibitor and can be used to study heart failure.
  • Description
    Imazodan, a small molecule compound with positive inotropic activity, is a selective type III phosphodiesterase inhibitor and can be used to study heart failure.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    PDE
  • Recptor
    PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    84243-58-3
  • Formula Weight
    240.26
  • Molecular Formula
    C13H12N4O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1CCC(=NN1)c1ccc(cc1)-n1ccnc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • HA-155

    HA155 is a boronic acid-based compound, inhibiting ATX with IC50 of 5.7 nM by selectively binding to its catalytic threonine.

  • Zaprinast

    Zaprinast (M&B 22948) is a potent, cGMP-specific phosphodiesterase inhibitor with IC50 of 0.5-0.76 and 0.15 uM for PDE5 and PDE6 respectively.

  • OPC18750 HCl

    OPC18750 HCl is a potential phosphodiesterase inhibitor with positive inotropic effects that can be used to study asthma, cancer, diabetes, and psychiatric disorders.